|Positive WB detected in||COLO 320 cells, rat brain tissue, HepG2 cells, SMMC-7721 cells|
|Positive IHC detected in||human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:3000|
|Immunohistochemistry (IHC)||IHC : 1:250-1:1000|
|Sample-dependent, check data in validation data gallery|
55206-1-AP targets PCSK9 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, rat samples.
|Tested Reactivity||human, rat|
|Cited Reactivity||human, rat, hamster|
|Host / Isotype||Rabbit / IgG|
|Full Name||proprotein convertase subtilisin/kexin type 9|
|Calculated molecular weight||74 kDa|
|Observed molecular weight||58-62 kDa, 72-78 kDa|
|GenBank accession number||NM_174936|
|Gene ID (NCBI)||255738|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.
Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases
PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer
Int J Mol Sci
Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity
Int J Mol Sci
Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.
The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.
Malak (Verified Customer) (11-30-2020)
The antibody works very well in IHC staining especially at pH6 and 1/100 dilution